Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Rises By 46.7%

Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,400 shares, a growth of 46.7% from the January 15th total of 3,000 shares. Based on an average trading volume of 13,300 shares, the days-to-cover ratio is currently 0.3 days.

Adlai Nortye Stock Down 2.2 %

Shares of ANL traded down $0.05 during midday trading on Monday, reaching $2.25. The stock had a trading volume of 10,769 shares, compared to its average volume of 3,371. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48. The firm's 50 day moving average price is $2.16 and its 200-day moving average price is $2.36.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.